Search Results 571-580 of 18313 for alopecia

1. Loncastuximab Tesirine in WM - Mayo Clinic

   Participants with ongoing >grade 1 toxicities from prior therapy (alopecia any grade and/or grade 2 neuropathy are permitted). - Participants with ...

2. A Study of Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery - Mayo Clinic

   All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5) grade =< 1 (except alopecia) at the time of ...

3. Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors - Mayo Clinic

   ... alopecia prior to C1D1; Age eighteen years or older; ECOG performance status 0-2, inclusive; Anticipated life expectancy of at least 12 weeks; Adequate bone ...

4. Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer - Mayo Clinic

   Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not ...

5. A Study Comparing Gemcitabine with or without AZD 1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   ... alopecia or peripheral neuropathy can also be included; Palliative radiation to < 10% of bone marrow is permissible if completed within one week of ...

6. https://www.mayoclinic.org/arabic_organization_concepts.xml

7. Study Of Datopotamab Deruxtecan Plus Carboplatin Or Cisplatin Versus Gemcitabine Plus Carboplatin Or Cisplatin In Participants With Locally Advanced Or Metastatic Urothelial Carcinoma - Mayo Clinic

   Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤1 or baseline.

8. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation - Mayo Clinic

   (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor.) ...

9. Tucatinib and Trastuzumab for Patients with HER2-positive Metastatic Colorectal Cancer - Mayo Clinic

   Alopecia and neuropathy, which must have resolved to ≤ Grade 2;; Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of ...

10. Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) - Mayo Clinic

    Complete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the subject received major surgery or ...